WO2005056027A2 - Lösungsmittel für biogene pharmazeutische wirkstoffe - Google Patents
Lösungsmittel für biogene pharmazeutische wirkstoffe Download PDFInfo
- Publication number
- WO2005056027A2 WO2005056027A2 PCT/DE2004/002713 DE2004002713W WO2005056027A2 WO 2005056027 A2 WO2005056027 A2 WO 2005056027A2 DE 2004002713 W DE2004002713 W DE 2004002713W WO 2005056027 A2 WO2005056027 A2 WO 2005056027A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- loxosceles
- species
- total
- solvent
- ants
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/648—Myriapods, e.g. centipedes or millipedes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/58—Reptiles
- A61K35/583—Snakes; Lizards, e.g. chameleons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/646—Arachnids, e.g. spiders, scorpions, ticks or mites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Definitions
- biogenic poisons began in the history of centuries as long ago as it was used to kill prey with poisoned weapons.
- Tumors the most dangerous and feared diseases of our time, are currently being combated in a very radical and less environmentally friendly way.
- the following can be used as simple, characteristic keywords: steel, radiation and chemotherapy.
- tumors if reasonably attainable, are in principle cut out with the steel of a knife, burned by a wide range of radiation, or destroyed by so-called chemotherapy with aggressive cytostatics that also attack healthy cells.
- a pharmaceutical active ingredient is known from DE 199 61 141 A1, in which it has been found that components of the spider venom from spiders of the Sicaridae family can be used for the treatment of tumor diseases.
- a peptide toxin from the poison of this type of spider, a further antagonistic substance obtained from the poison and / or a combination of these components are used medically.
- This active ingredient can be used for the treatment of tumor diseases and in parallel or in support of tumor operations and residual tumor tissue can be destroyed.
- Genetically modified body cells tumor cells
- the solvent according to the invention is composed of several components.
- Tarantula D4 are incorporated into 15 ml of 0.9% NaCI solution as a basic component. Tarantula D4 is mixed in a homeopathic manner with shaking to the center of the earth with 15 ml of the 0.9 percent NaCI solution.
- homeopathy the patient receives the medication in question not in his mother tincture but in a dilution stage.
- the D dilution levels are made by filling 1/10 of the stock solution with 9/10 alcohol and then shaking. This gives the first dilution D1.
- Loxosceles are in the warmer to the tropical areas of
- North America, Central America, South America and the Caribbean represented about 50 species.
- the animals usually colored in brown tones, reach a length of the body (without
- the bites are registered, which have symptoms similar to a mosquito bite.
- necrotic arachndism There is the term "necrotic arachndism”.
- Necrosis is also known after bites from other spiders. 3. Due to different proportions of the total poison cocktails used, it is sometimes necessary to rub the total poison cocktail in anhydrous formic acid, which in turn is added 1 to 2 ml of the total extract by Bulldog-ants. This amount refers to an amount of the total poison cocktail of 10 ml.
- the Bulldog - ants are ants that belong to the Myrmicinae family.
- Ants on earth They can reach a length of up to 40 millimeters. They are diurnal and come in different sizes and colors.
- the Bulldog ants have a long head, big eyes and strong jaws.
- Another type of bulldog - ant is small, black, and leaps forward. This type creates jumps up to 20 centimeters high.
- the special pharmaceutical active ingredient is then incorporated into the solvent thus obtained for the particular application in question.
- the solvents alone have a tumor-destroying effect, which can be seen in cell tests for brain tumors, gastrointestinal tumors and individual breast cancer patients
- the solvent according to the invention is particularly suitable for the following applications: 1. For the treatment of cancerous tissue from the area of the kidney tissue.
- Crotalus poison has particularly lysing effects, in accordance with their molecular weights.
- the poison from spiders of the species Lycosa tarantula is suitable as a basic substance for combating this special type of cancer.
- the peptide toxins, as well as optionally the antagonistic substances and / or the penetrating substance with very specific molecular weights, have proven to be particularly effective in combating this particular type of cancer. These are the molecular weights with the following values in kDa: 18, 54, 108 and 124.
- the peptide toxins as well as optionally the antagonistic substances and / or the penetrating substances with the special molecular weights of 27 kDa or 31 kDa, proved to be particularly effective. 4.
- the peptide toxins as well as optionally the antagonistic substances and / or the penetrating substances with the special molecular weights of 27 kDa or 31 kDa, proved to be particularly effective. 4.
- the peptide toxins as well as optionally the antagonistic substances and / or the penetrating substances from the poison of the following animal species, have a corresponding effect: a) among the spiders of the Loxoscelidae family, the genus Loxosceles, in particular, Loxosceles rufipes, Loxosceles sp , (Mallorca), Loxosceles sp. (Menorca), Loxosceles sp. (lbica) b) among the scorpions the genus Euscorpius, EuscorpiusSc, Euscorpius cingulata, Euscorpius Cycoso spp.
- hemocyanin which is obtained from the following animal species: 1. Avicularia species 2. Acanthoscurria species 3. Pamphobeteus species 4. Vitalius species
- Dolastin which comes mainly from the animals of the 5th Dolabella species is won.
- Dolabella auricularia also known as the sea rabbit, is particularly preferred.
- Dolastin 10 obtained from Dolabella auricularia has the CAS registry number
- Kahalalide F brand name obtained from the sea nudibranch 6. Elysia rufescens.
- herpes simplex and herpes zoster 7.
- the active ingredient according to the invention is essentially produced from a combination of substances obtained from the mouth secretions of certain turtles, with components from the juice of Euphorbia plants. These are turtles of the Testudinidae family (tortoises) a) genus Kinixys spp (jointed turtles), and b) of the genus Homopus spp. (Flat turtles), and from the genus Testudo (actual tortoises) c) of the subgenus Geochelone
- the active ingredient according to the invention is essentially produced from a combination of a homeopathic substance, with a substance that is derived from the cleaned mouth secretion of one of the following species from the Varanidae (monitor lizard) family is obtained: a) Varanus storii or dwarf monitor lizard b) Varanus gilleni or Gillen - monitor lizard c) Varanus acanthurus or barbed monitor monitor lizard d) Varanus kingorum or king monitor lizard e) Varanus boehmei (also boehmi )
- the homeopathic substance is preferably Tarantula D 4.
- the active substance in question is essentially produced from a combination of homeopathic substances with a substance obtained from the oral secretion of one of the following species of the Lacertidae family (lizards): a) Eremias genus b) Acanthodactylus genus c) Lacerta genus with the Archaeolacerta subspecies d) genus Takydromus, and e) genus Gallotia
- the substances of the oral secretion should have a molecular weight that is between 5 kDa and 30 kDa.
- the active substance in question is essentially produced from a combination of a mixture of homeopathic substances with a substance derived from the Mouth secretions of the following animal species from the Varanidae family (monitor lizards) and from animals from the Eublepharidae family (geckos) are obtained.
- Varanus gilani or Gillen - Varan b) Varanus komodoensis or Komodo - Varan, c) Varanus prasinus or Smaragdvaran d) Varanus panoptes
- the active ingredient required here is in one case a combination of the poison and the oral secretion of the Anger snake or the sand racing snake, in the other case only the oral secretion of the dice snake, the viper snake or the garter snake. It is important to ensure that substances are used whose molecular weight is between 8 kDa and 30 kDa.
- Vipera berus b) Vipera wagneri c) Vipera urini, and d) Vipera aspis
- Penetrants must have a molecular weight of 28 kDa, 32 kDa or 35 kDa. 13. Pharmaceutical slimming products through the targeted destruction of fat cells.
- Unwanted fat cells like unwanted tumor cells, are destroyed by a combination of active ingredients obtained from the poison of the following animal species.
- Mimica scabrinodis (ant species) spp. related species b) Mimica scabrinodis (ant species) spp. related species
- Pheidole pallidula (ant species) spp. related species
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Insects & Arthropods (AREA)
- Tropical Medicine & Parasitology (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE112004002737T DE112004002737D2 (de) | 2003-12-11 | 2004-12-10 | Lösungsmittel für biogene pharmazeutische Wirkstoffe |
EP04802918A EP1699473A2 (de) | 2003-12-11 | 2004-12-10 | Lösungsmittel für biogene pharmazeutische wirkstoffe |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10357970A DE10357970A1 (de) | 2003-12-11 | 2003-12-11 | Lösungsmittel für biogene pharmazeutische Wirkstoffe |
DE10357970.2 | 2003-12-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005056027A2 true WO2005056027A2 (de) | 2005-06-23 |
WO2005056027A3 WO2005056027A3 (de) | 2005-07-21 |
Family
ID=34638617
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DE2004/002713 WO2005056027A2 (de) | 2003-12-11 | 2004-12-10 | Lösungsmittel für biogene pharmazeutische wirkstoffe |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1699473A2 (de) |
DE (2) | DE10357970A1 (de) |
WO (1) | WO2005056027A2 (de) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007065925A2 (de) * | 2005-12-07 | 2007-06-14 | Toximed Gmbh | Zusammensetzung zur behandlung von melanomen und hautunreinheiten sowie kosmetisches hautpflegemittel |
WO2007071716A1 (de) * | 2005-12-20 | 2007-06-28 | Toximed Gmbh | Pharmazeutische zusammensetzung zur behandlung von tumoren und bestimmten virenerkrankungen |
CN102716392A (zh) * | 2012-06-01 | 2012-10-10 | 蒋金洲 | 一种治疗疮、脓肿、疱疹的外用中药组合物 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102005033645A1 (de) | 2005-07-19 | 2007-02-01 | Toximed Gmbh | Pharmazeutischer Wirkstoff-Kombination zur Behandlung von Multipler Sklerose |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19961141A1 (de) * | 1999-12-17 | 2001-07-26 | Mack Gerd R | Pharmazeutische Zusammensetzung aus Spinnengiften sowie deren Herstellung und Verwendung zur Behandlung von Tumorerkrankungen |
DE10324861A1 (de) * | 2003-06-02 | 2004-12-23 | Toximed Gmbh | Pharmazeutischer Wirkstoff |
-
2003
- 2003-12-11 DE DE10357970A patent/DE10357970A1/de not_active Withdrawn
-
2004
- 2004-12-10 WO PCT/DE2004/002713 patent/WO2005056027A2/de not_active Application Discontinuation
- 2004-12-10 EP EP04802918A patent/EP1699473A2/de not_active Withdrawn
- 2004-12-10 DE DE112004002737T patent/DE112004002737D2/de not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19961141A1 (de) * | 1999-12-17 | 2001-07-26 | Mack Gerd R | Pharmazeutische Zusammensetzung aus Spinnengiften sowie deren Herstellung und Verwendung zur Behandlung von Tumorerkrankungen |
DE10324861A1 (de) * | 2003-06-02 | 2004-12-23 | Toximed Gmbh | Pharmazeutischer Wirkstoff |
Non-Patent Citations (2)
Title |
---|
N N: "HomŸopathisches Repetitorium, Tarantula" HOMOEOPATHISCHES REPETITORIUM, 1987, Seiten 288-289, XP002307491 * |
SOROCEANU L ET AL: "USE OF CHLOROTOXIN FOR TARGETING OF PRIMARY BRAIN TUMORS" CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, Bd. 58, Nr. 21, 1. November 1998 (1998-11-01), Seiten 4871-4879, XP001146137 ISSN: 0008-5472 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007065925A2 (de) * | 2005-12-07 | 2007-06-14 | Toximed Gmbh | Zusammensetzung zur behandlung von melanomen und hautunreinheiten sowie kosmetisches hautpflegemittel |
WO2007065925A3 (de) * | 2005-12-07 | 2007-09-07 | Toximed Gmbh | Zusammensetzung zur behandlung von melanomen und hautunreinheiten sowie kosmetisches hautpflegemittel |
WO2007071716A1 (de) * | 2005-12-20 | 2007-06-28 | Toximed Gmbh | Pharmazeutische zusammensetzung zur behandlung von tumoren und bestimmten virenerkrankungen |
CN102716392A (zh) * | 2012-06-01 | 2012-10-10 | 蒋金洲 | 一种治疗疮、脓肿、疱疹的外用中药组合物 |
Also Published As
Publication number | Publication date |
---|---|
EP1699473A2 (de) | 2006-09-13 |
DE112004002737D2 (de) | 2006-11-23 |
WO2005056027A3 (de) | 2005-07-21 |
DE10357970A1 (de) | 2005-07-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1244462B1 (de) | Pharmazeutische zusammensetzung aus spinnengiften sowie deren herstellung und verwendung zur behandlung von tumorerkrankungen | |
DE10024383B4 (de) | Mit toxischen Substanzen beladene dendritische Zellen | |
DE102005038768A1 (de) | Pharmazeutischer Wirkstoff gegen Borreliose | |
WO2005002604A1 (de) | Pharmazeutischer wirkstoff gegen tumorerkrankungen | |
WO2005056027A2 (de) | Lösungsmittel für biogene pharmazeutische wirkstoffe | |
WO2007060252A2 (de) | Pharmazeutischer wirkstoff zur behandlung von hepatitis, borreliose und multipler sklerose | |
WO2006134166A2 (de) | Pharmazeutischer wirkstoff zur überwindung der blut-hirn-schranke in verbindung mit einem aus biogenen giften gewonnenen wirkstoff gegen hirntumore | |
EP2155335B1 (de) | Pharmazeutische zusammensetzung, verwendung der pharmazeutischen zusammensetzung zur behandlung eines hirntumors, herstellungsverfahren derselben sowie ein kit of parts, enthaltend die pharmazeutische zusammensetzung | |
DE102005027478A1 (de) | Pharmazeutischer Wirkstoff gegen Nierenzellkarzinome und dessen Lösungsmittel | |
EP1754486A2 (de) | Pharmazeutischer Wirkstoff zur Behandlung von Hepatitis, Borreliose und Multipler Sklerose | |
DE102005011111A1 (de) | Pharmazeutischer Wirkstoff zur Beladung dendritischer Zellen und dessen Lösungsmittel | |
DE102005060932A1 (de) | Pharmazeutische Zusammensetzung zur Behandlung von Tumoren und bestimmten Virenerkrankungen | |
DE102004008417A1 (de) | Pharmazeutischer Wirkstoff gegen Lebertumore und Nierenzellkarzinome | |
DE10324062A1 (de) | Pharmazeutischer Wirkstoff | |
DE10322656A1 (de) | Pharmazeutischer Wirkstoff | |
DE10333192A1 (de) | Pharmazeutischer Wirkstoff gegen Warzen, Herpes simplex und Herpes zoster | |
WO2005007177A1 (de) | Pharmazeutischer wirkstoff gegen magengeschwüre | |
DE10324861A1 (de) | Pharmazeutischer Wirkstoff | |
WO2005002616A1 (de) | Pharmazeutischer wirkstoff gegen tumoren enthaltend loxoscelidae spinnengift | |
DE10341307A1 (de) | Pharmarzeutischer Wirkstoff gegen Brustkrebs | |
WO2005002494A2 (de) | Pharmazeutischer wirkstoff gegen prostatakarzinome | |
WO2005004887A1 (de) | Pharmazeutischer wirkstoff gegen kolonkarzinome und andere tumorarten | |
WO2005027942A1 (de) | Pharmazeutischer wirkstoff aus schlangengift gegen melanome | |
WO2005103231A2 (de) | Mit toxischen substanzen beladene dendritische zellen zur behandlung von nierenzellkarzinomen | |
DE102005058455A1 (de) | Pharmazeutischer Wirkstoff zur Behandlung von Melanomen und Hautunreinheiten |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004802918 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1120040027373 Country of ref document: DE |
|
WWP | Wipo information: published in national office |
Ref document number: 2004802918 Country of ref document: EP |
|
REF | Corresponds to |
Ref document number: 112004002737 Country of ref document: DE Date of ref document: 20061123 Kind code of ref document: P |
|
WWE | Wipo information: entry into national phase |
Ref document number: 112004002737 Country of ref document: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2004802918 Country of ref document: EP |